Seattle, WA — (September 12, 2022)  Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development

BOSTON, Aug. 29, 2022 — Yumanity Therapeutics, Inc. (“Yumanity”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and

Kineta Announces Appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer Seattle, WA — (June 28, 2022) Kineta, Inc. (“Kineta”

Kineta Announces Strategic Research Collaboration and License Agreement with Merck Focused on Accelerating the Development of New Treatments for Neurodegenerative

Kineta Presents New Preclinical Data and Phase 1/2 Clinical Trial Design of KVA12.1 at the Tumor Myeloid-Directed Therapies Summit Seattle,

Yumanity Therapeutics announces definitive agreements for two strategic transactions Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as

Kineta Presenting in Multiple Sessions at the Preclinical Immuno-oncology Online 2022 Seattle, WA — (May 18, 2022) Kineta, Inc., a

Kineta Unveils New Preclinical Data on its Anti-CD27 Agonist Lead Antibodies at AACR 2022 Seattle, WA — (April 13, 2022)

Kineta to Present Poster on Anti-CD27 Agonist Antibody Program at the AACR Annual Meeting 2022 Seattle, WA — (March 21,